Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin

Infection and Immunity

Volumn 65, Issue 7, 1997, Pages 2821-2828

  Douce, Gill ^a   Fontana, Mariarita ^b   Pizza, Mariagrazia ^b   Rappuoli, Rino ^b   Dougan, Gordon ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; CHOLERA; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE;

EID: 0030940814     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.7.2821-2828.1997     Document Type: Article

References (39)

1. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908-2914.
2. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
3. Cropley, I., G. Douce, M. Roberts, S. Chatfield, M. Pizza, I. Marsili, R. Rappuoli, and G. Dougan. 1995. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Vaccine 13:1643-1648.
4. Debard, N., D. Buzoni-Gatel, and D. Bout. 1996. Intranasal immunization with SAG1 prolein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect. Immun. 64:2158-2166.
5. De Haan, L., W. R. Verweij, I. K. Feil, T. H. Lijnema, W. G. Hol, E. Agsteribbe, and J. Wilschut. 1996. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin, Infect. Immun. 64:5413-5416.
6. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-23.
7. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. 1996. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:974-979.
8. Douce, G., M. Pizza, M. Roberts, R. Rappuoli, and G. Dougan. Mutant pertussis and Escherichia coli heat-labile toxins as adjuvants for enhancing local and systemic immune responses to coadministered, nonliving antigens, p. 253-262. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and J. S. Cobon (ed.), New generation vaccines, 2nd ed., in press.
9. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1648.
10. Elson, C. J., and W. Ealding. 1984. Generalised systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132:2736-2743.
11. Fontana, M. R., R. Manetti, V. Giannelli, C. Magagnoli, A. Marchini, R. Olivieri, M. Domenighlni, R. Rappuoli, and M. Pizza. 1995. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2356-2360.
12. Giannelli, V., M.-R. Fontana, M. M. Giuliani, D. Guangcai, R. Rappuoli, and M. Pizza. 1997. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 65:331-334.
13. Holmgren, J., P. Fredman, M. Lindblad, A.-M. Svennerholm, and L. Svennerholm. 1982. Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect. Immun. 38:424-433.
14. Hornquist, E., D. Grdic, T. Mak, and N. Lycke. 1996. CD8-deficient mice exhibit augmented mucosal immune responses and intact adjuvant effects to cholera toxin. Immunology 87:220-229.
15. Jackson, R. J., K. Fujihashi, J. Xu Amano, H. Kiyono, C. O. Elson, and J. R. McGhee. 1993. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61:4272-4279.
16. Lee, A., and M. Chen. 1994. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit whole-cell vaccine. Infect. Immun. 62:3594-3597.
17. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510-550.
18. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301-308.
19. Lycke, N., T. Tsuji, and J. Holmgren. 1492. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
20. Lycke, N. Y. 1993. Cholera toxin promotes B cell isotype switching by two different mechanisms. J. Immunol. 150:4810-4821.
21. Magagnoli, C., R. Manetti, M. K. Fontana, V. Giannelli, M. M. Giuliani, R. Rappuoli, and M. Pizza. 1996. Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin. Infect. Immun. 64:5434-5438.
22. Marchetti, M., B. Arico, D. Burroni, N. Figura, R. Rappuoli, and P. Ghiara. 1995. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 267:1655-1658.
23. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann et al. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4029,
24. Nakagawa, I., I. Takahashi, H. Kiyono, J. R. McGhee, and S. Hamada. 1996. Oral immunisation with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches. J. Infect. Dis. 173:1428-1436.
25. Pizza, M., M. Domenighini, W. Hol, V. Giannelli, M. R. Fontana, M. Guiliani, C. Magagnoli, S. Peppoloni, K. Manetti, and K. Rappuoli. 1994. Probing the structure activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14:51-60.
26. Pizza, M., M. R. Fontana, M. M. Giuliani, M. Domenighini, C. Magagnoli, V. Giannelli, D. Nucci, W. Hol, R. Manetti, and R. Rappuoli. 1994. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 180:2147-2153.
27. Roberts, M., A. Bacon, R. Rappuoli, M. Pizza, I. Cropley, G. Douce, G. Dougan, M. Marinaro, J. McGhee, and S. Chatfield. 1995. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63:2100-2108.
28. Rollwagen, F. M., N. D. Pacheco, J. D. Clements, O. Pavlovskis, D. M. Rollins, and R. I. Walker. 1993. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine 11:1316-1320.
29. Sixma, T. K., K. H. Kalk, B. A. M. Vanzanten, Z. Dauter, J. Kingma, B. Witholt, and W. G. J. Hol. 1993. Refined structure of Escherchia coli heat-labile enterotoxin. a close relative of cholera toxin. J. Mol. Biol. 230:890-918.
30. Sixma, T. K., S. E. Pronk, K. H. Kalk, E. S. Wartna, B. A. Vun Zanten, B. Witholt, and W. G. Hol. 1991. Crystal structure of cholera related heat labile toxin from E. coli. Nature 351:371-377.
31. Spangler, B. D. 1992. Structure and function of cholera toxin and related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622-647.
32. Spicer, E. K., W. M. Kavanaugh, W. S. Dallas, S. Falkow, W. H. Konigsberg, and D. K. Schafer. 1981. Sequence homologies between A subunits of Escherichia coli and Vibrio cholerae enterotoxins. Proc. Natl. Acad. Sci. USA 78:50-54.
33. Sugii, S., and T. Tsuji. 1989. Binding specificies of heat-labile enterotoxins isolated from porcine and human enterotoxigenic Escherichia coli for different gangliosides. Can. J. Microbiol. 35:670-673.
34. Sun, J.-B., J. Holmgren, and C. Czerkinsky. 1994. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91:10795-10799.
35. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627-635.
36. Tamura, S., H. Funato, T. Nagamine, C. Aizawa, and T. Kurata. 1989. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine 7:503-505.
37. Tamura, S., Y. Ito, H. Asanumu, Y. Hirabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, and T. Kurata. 1992. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:981-988.
38. Tamura, S., A. Yamanaka, M. Shimohara, T. Tomita, K. Komase, Y. Tsuda, Y. Suzuki, T. Nagamine, K. Kawahara, H. Danbara et al. 1994. Synergistic action of cholera toxin 13 subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12:419-426.
39. Vajdy, M., M. H. Kosco Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 181:41-53.